3/12
08:03 am
nerv
Minerva Neurosciences (NERV) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock, up from $4.00.
Medium
Report
Minerva Neurosciences (NERV) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock, up from $4.00.
3/12
07:00 am
nerv
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Medium
Report
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
3/11
09:59 am
nerv
Minerva Neurosciences files $200M mixed shelf registration [Seeking Alpha]
Medium
Report
Minerva Neurosciences files $200M mixed shelf registration [Seeking Alpha]
3/11
07:37 am
nerv
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Medium
Report
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates [Yahoo! Finance]
3/11
07:00 am
nerv
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Medium
Report
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
3/4
07:13 am
nerv
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference [Yahoo! Finance]
Low
Report
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference [Yahoo! Finance]
3/4
07:00 am
nerv
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Low
Report
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
2/16
06:11 am
nerv
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most [Yahoo! Finance]
Low
Report
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most [Yahoo! Finance]
2/4
02:18 am
nerv
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]
Low
Report
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]
2/3
07:50 pm
nerv
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
Low
Report
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
1/26
07:00 am
nerv
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Low
Report
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
1/11
01:03 am
nerv
Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at
Wall S
Medium
Report
Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at
Wall S